Clopidogrel Bisulfate
Product Images NDC 62034-017

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 62034-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

300mg 3x10ud 30ct (62034 017 73)

Label for Clopidogrel tablets, USP 300 mg, unit-dose packaging containing 30 tablets (3 x 10). The label displays the NDC 62034-017-73 and indicates prescription use only. It includes warnings about dispensing a medication guide and child-resistant packaging. The drug is marketed by Blenheim Pharmacal, Inc. and the tablets are oval, brownish, marked with "121" and "SG".*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal dot plot showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) with mean values and 90% confidence intervals. The PPIs listed are Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with data points plotted along a scale from 0.4 to 1.4.*

FDA Label Image

Figure 2 (Clopidogrel Fig2)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between placebo (+ aspirin) and clopidogrel bisulfate (+ aspirin). The graph shows lower event rates for clopidogrel bisulfate over time with statistical significance noted (P=0.00009).*

FDA Label Image

Figure 3 (Clopidogrel Fig3)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various patient characteristics and concomitant therapies. The chart presents categories such as baseline diagnosis, age, gender, race, medical history, and medication use with corresponding event rates and hazard ratios.*

FDA Label Image

Figure 4 (Clopidogrel Fig4)

A survival curve chart comparing death percentages before first discharge across 28 days since randomization for Clopidogrel bisulfate and placebo groups. The graph shows death percentages on the y-axis and days since randomization on the x-axis, with annotations noting 1845 deaths (8.1%) for placebo and 1726 deaths (7.5%) for Clopidogrel bisulfate, indicating a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure 5 (Clopidogrel Fig5)

A Kaplan-Meier curve chart depicting the percentage of patients with death, reinfarction, or stroke before first discharge over days since randomization (up to 28 days). It compares placebo and Clopidogrel groups, showing cumulative event rates, with Clopidogrel demonstrating lower event incidence and a noted 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Figure 6 (Clopidogrel Fig6)

A forest plot chart presenting odds ratios and confidence intervals for events (%) between Clopidogrel bisulfate and placebo groups by several baseline categories including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. Data shows total events and statistical heterogeneity tests with p-values. The graph includes markers for odds ratio 0.75 to 1.5 and a proportional reduction summary.*

FDA Label Image

Figure 7 (Clopidogrel Fig7)

A forest plot chart showing event percentages and odds ratios comparing Clopidogrel and placebo groups across categories: Killip class, previous myocardial infarction, and infarct location. It includes confidence intervals, heterogeneity statistics, and a note on a proportional reduction in events with Clopidogrel.*

FDA Label Image

Figure 8 (Clopidogrel Fig8)

A line graph comparing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up between Clopidogrel and Aspirin treatments. The x-axis represents months of follow-up, and the y-axis shows cumulative event rate percentage. The graph includes a p-value of 0.045 indicating statistical comparison between the two treatments.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate, showing its molecular configuration including thiophene, piperidine rings, and functional groups with sulfate (H2SO4) indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.